Pfizer declares 'first-ever' PhIII win for RSV vaccine in infants — and it's steering straight to FDA
In a first, Pfizer says it’s demonstrated that it can protect infants from respiratory syncytial virus by vaccinating their mothers during pregnancy.
Pfizer is stopping …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
